Here are four notes:
1. CellRight Technologies boasts an orthopedic portfolio with human-derived bone graft products.
2. Tissue Regenix develops soft tissue products featuring its patented decellularisation dCELL Technology.
3. Tissue Regenix would leverage CellRight Technologies’ San Antonio-based tissue bank, opening a door to the U.S. market.
4. The proposed acquisition would allow Tissue Regenix to enter the U.S. orthopedics market by 2018, honing in on ligament reconstruction.
More articles on devices:
Spinal cord stimulation market to grow at a 9.2% CAGR through 2021 — 5 observations
4 key notes on Stryker mid-year
Dr. Steven DeLuca performs 1st surgery in Premia Spine’s FDA pivotal study: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
